Streetbeat News

MDGL

Madrigal Pharmaceuticals, Inc.

https://www.madrigalpharma.com

Industry

Biotechnology

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Open

303.29

Mkt cap

6.3B

Volume

934K

High

303.29

P/E Ratio

-11.53

52-wk high

368.29

Low

272.72

Div yield

N/A

52-wk low

166.00

HC Wainwright & Co. analyst Ed Arce maintains a Buy rating on Madrigal Pharmaceuticals (MDGL) but lowers the price target from $425 to $390.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 7:32 pm

Citigroup analyst David Lebovitz maintains a Buy rating on Madrigal Pharmaceuticals (MDGL) but lowers the price target from $389 to $382.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 7:16 pm

JMP Securities analyst Jonathan Wolleben maintains a Market Outperform rating on Madrigal Pharmaceuticals (MDGL) but lowers the price target from $397 to $381.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 6:00 pm

In Tuesday's pre-market session, several healthcare stocks showed significant movement. FibroGen, Envoy Medical, iSpecimen, NovaBay Pharmaceuticals, GT Biopharma, and Esperion Therapeutics were among the gainers, with notable increases in their stock prices following their Q1 earnings reports. Conversely, Helius Medical Tech, Cellectis, Eledon Pharma, Fresenius Medical Care, Madrigal Pharmaceuticals, and Context Therapeutics experienced declines.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 12:06 pm

Madrigal Pharmaceuticals reported a Q1 2024 GAAP EPS loss of $(7.38), missing the consensus estimate of $(6.17) by 19.61%.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:21 am

Today's session highlighted significant whale activity in the health care sector, focusing on options trading for stocks like BMY, ARDX, AMGN, BDX, HROW, CI, MDGL, DXCM, LLY, and TMDX. The trades varied in sentiment, with some being bullish and others bearish, across a range of expiration dates and strike prices. This activity could indicate upcoming volatility or trading opportunities in these stocks.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 5:35 pm

B of A Securities has initiated coverage on Madrigal Pharmaceuticals (MDGL) with an Underperform rating and set a price target of $150.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 10:19 am

Evercore ISI Group analyst Liisa Bayko has maintained an Outperform rating on Madrigal Pharmaceuticals (NASDAQ:MDGL) and increased the price target from $325 to $405.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 3:26 pm

Madrigal Pharmaceuticals announced the pricing of its upsized $600 million public offering of 750,000 shares at $260 per share, causing its stock to trade lower.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 11:12 am

Madrigal Pharmaceuticals, Inc. (MDGL) has announced the pricing of an upsized public offering of 750,000 shares at $260 per share, along with pre-funded warrants for 1,557,692 shares at $259.9999 each. This move is aimed at raising funds to support its efforts in developing treatments for nonalcoholic steatohepatitis (NASH).

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 6:13 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.